---
figid: PMC9250839__TCA-13-1961-g003
pmcid: PMC9250839
image_filename: TCA-13-1961-g003.jpg
figure_link: /pmc/articles/PMC9250839/figure/tca14474-fig-0003/
number: FIGURE 3
figure_title: ''
caption: Galectin‐3 regulated the HER2/EGFR/PI3K/AKT pathway. (a) Western blot analysis
  of AKT, PTEN, and EGFR (β‐actin as a loading control), p‐HER2, p‐AKT, p‐PI3K, and
  p‐ERK1/2. (b) qRT‐PCR analysis of EGFR, AKT, PTEN, and HER2 mRNA; ACTB mRNA was
  used as a loading control. (c) Immunofluorescence images of HER2 (red) and DAPI
  (blue). Scale bars, 100 μm. The significant differences are indicated by asterisk
  (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
article_title: Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy
  and stemness in HER2‐positive breast cancer cells.
citation: Yuqiu Chen, et al. Thorac Cancer. 2022 Jul;13(13):1961-1973.
year: '2022'

doi: 10.1111/1759-7714.14474
journal_title: Thoracic Cancer
journal_nlm_ta: Thorac Cancer
publisher_name: John Wiley & Sons Australia, Ltd

keywords:
- cancer cell stemness
- galectin‐3
- HER2‐positive breast cancer
- trastuzumab resistance

---
